---
layout: default
title: Regorafenib
description: "Regorafenib 的老藥新用潛力分析。高證據等級 L2，包含 8 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 高證據等級 (L1-L2)
nav_order: 145
evidence_level: L2
indication_count: 8
---

# Regorafenib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L2</strong> | 預測適應症: <strong>8</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Regorafenib：從大腸直腸癌到脂肪肉瘤

## 一句話總結

<p class="key-answer" data-question="Regorafenib 可以用於治療什麼新適應症？">
Regorafenib 是一種多標靶激酶抑制劑，原本用於轉移性大腸直腸癌、胃腸道間質腫瘤（GIST）和肝細胞癌的治療。TxGNN 模型預測它可能對**脂肪肉瘤 (Liposarcoma)** 有效，目前有 **2 個臨床試驗**和 **9 篇文獻**支持這個方向。
</p>

## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 轉移性大腸直腸癌、胃腸道間質腫瘤、肝細胞癌 |
| 預測新適應症 | liposarcoma、ovarian myxoid liposarcoma、clear cell renal carcinoma、unclassified renal cell carcinoma、renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions、renal cell carcinoma associated with neuroblastoma、childhood kidney cell carcinoma、vulva sarcoma |
| TxGNN 預測分數 | 99.76% |
| 證據等級 | L2 |
| 台灣上市 | 已上市 |
| 許可證數 | 1 張 |
| 建議決策 | Proceed with Guardrails |





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. liposarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.76%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Regorafenib 是一種口服多標靶激酶抑制劑，可抑制多種參與腫瘤血管新生、腫瘤微環境和腫瘤增殖的激酶，包括：</p>
<ul>
<li>VEGFR1-3（血管新生）</li>
<li>TIE2（血管新生）</li>
<li>PDGFR-β（腫瘤微環境）</li>
<li>FGFR（纖維母細胞生長因子受體）</li>
<li>KIT、RET、RAF（腫瘤增殖）</li>

</ul>
<p>脂肪肉瘤是一種源自脂肪組織的惡性腫瘤，屬於軟組織肉瘤。與大腸直腸癌和 GIST 類似，脂肪肉瘤的生長和轉移也依賴血管新生和特定的信號傳導途徑。</p>

<p>Regorafenib 的多標靶特性使其在抑制腫瘤血管新生和腫瘤微環境方面具有潛在優勢。已有多項臨床試驗（包括 SARC024 和 REGOSARC）探討 regorafenib 在軟組織肉瘤中的療效。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02048371" target="_blank">NCT02048371</a></td><td>PHASE2</td><td>COMPLETED</td><td>131</td><td>SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01900743" target="_blank">NCT01900743</a></td><td>PHASE2</td><td>COMPLETED</td><td>219</td><td>Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarco...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29902612/" target="_blank">29902612</a></td><td>2018</td><td>Article</td><td>European journal of cancer (Ox</td><td>Efficacy and safety of regorafenib compared to placebo and to post-cross-over re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33290314/" target="_blank">33290314</a></td><td>2021</td><td>Article</td><td>Anti-cancer drugs</td><td>Efficacy and safety of anlotinib in patients with unresectable or metastatic wel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29931504/" target="_blank">29931504</a></td><td>2018</td><td>Article</td><td>Targeted oncology</td><td>Growing Role of Regorafenib in the Treatment of Patients with Sarcoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27751846/" target="_blank">27751846</a></td><td>2016</td><td>Article</td><td>The Lancet. Oncology</td><td>Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40975452/" target="_blank">40975452</a></td><td>2025</td><td>Article</td><td>Critical reviews in oncology/h</td><td>Maintenance after first-line treatment for advanced soft tissue sarcoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32701199/" target="_blank">32701199</a></td><td>2020</td><td>Article</td><td>The oncologist</td><td>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Ve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25884155/" target="_blank">25884155</a></td><td>2015</td><td>Article</td><td>BMC cancer</td><td>Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28295221/" target="_blank">28295221</a></td><td>2017</td><td>Article</td><td>Cancer</td><td>REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarco...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26266019/" target="_blank">26266019</a></td><td>2015</td><td>Article</td><td>Rare tumors</td><td>Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. ovarian myxoid liposarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. clear cell renal carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.47%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03475953" target="_blank">NCT03475953</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>747</td><td>A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24756792/" target="_blank">24756792</a></td><td>2014</td><td>Article</td><td>Recent results in cancer resea</td><td>Regorafenib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30069758/" target="_blank">30069758</a></td><td>2018</td><td>Article</td><td>Recent results in cancer resea</td><td>Regorafenib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24308791/" target="_blank">24308791</a></td><td>2014</td><td>Article</td><td>Expert review of clinical phar</td><td>Novel tyrosine kinase inhibitors for renal cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24387233/" target="_blank">24387233</a></td><td>2014</td><td>Article</td><td>Expert opinion on investigatio</td><td>Fibroblast growth factor receptors as therapeutic targets in clear-cell renal ce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24309512/" target="_blank">24309512</a></td><td>2014</td><td>Article</td><td>Cancer biology &amp; therapy</td><td>Multi-kinase inhibition in ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23334510/" target="_blank">23334510</a></td><td>2013</td><td>Article</td><td>Current oncology reports</td><td>Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with pote...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30304963/" target="_blank">30304963</a></td><td>2018</td><td>Article</td><td>Expert review of anticancer th</td><td>Nivolumab for the treatment of hepatocellular carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22959186/" target="_blank">22959186</a></td><td>2012</td><td>Article</td><td>The Lancet. Oncology</td><td>Regorafenib for patients with previously untreated metastatic or unresectable re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41324163/" target="_blank">41324163</a></td><td>2026</td><td>Article</td><td>The Korean journal of physiolo</td><td>Drug repositioning of regorafenib for renal cell carcinoma identifies DDR2‑assoc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38761350/" target="_blank">38761350</a></td><td>2024</td><td>Article</td><td>Targeted oncology</td><td>Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27581086/" target="_blank">27581086</a></td><td>2016</td><td>Article</td><td>Biochimica et biophysica acta</td><td>The interaction of sorafenib and regorafenib with membranes is modulated by thei...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29956623/" target="_blank">29956623</a></td><td>2018</td><td>Article</td><td>Current drug metabolism</td><td>Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-de...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33419029/" target="_blank">33419029</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immun...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28703624/" target="_blank">28703624</a></td><td>2017</td><td>Article</td><td>Future oncology (London, Engla</td><td>Cabozantinib in the treatment of hepatocellular carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23700287/" target="_blank">23700287</a></td><td>2013</td><td>Article</td><td>Investigational new drugs</td><td>Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23981115/" target="_blank">23981115</a></td><td>2014</td><td>Article</td><td>British journal of clinical ph</td><td>Incidence and relative risk of hepatic toxicity in patients treated with anti-an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28166200/" target="_blank">28166200</a></td><td>2017</td><td>Article</td><td>Oncogene</td><td>Upregulation of MARCKS in kidney cancer and its potential as a therapeutic targe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36583425/" target="_blank">36583425</a></td><td>2023</td><td>Article</td><td>Journal of the American Heart </td><td>Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22959187/" target="_blank">22959187</a></td><td>2012</td><td>Article</td><td>The Lancet. Oncology</td><td>Choosing the right option for renal-cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33436042/" target="_blank">33436042</a></td><td>2021</td><td>Article</td><td>Journal of hematology &amp; oncolo</td><td>The integration of immune checkpoint inhibitors with VEGF targeted agents in adv...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. unclassified renal cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. renal cell carcinoma associated with neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. childhood kidney cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. vulva sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛部藥輸字第XXXXXX號 | 癌瑞格膜衣錠40毫克 | 膜衣錠 | 大腸直腸癌、胃腸道間質腫瘤、肝細胞癌 |

## 細胞毒性

| 項目 | 內容 |
|------|------|
| 細胞毒性分類 | 標靶藥物（多標靶激酶抑制劑） |
| 骨髓抑制風險 | 低至中度（可能出現血小板減少） |
| 致吐性分級 | 低度 |
| 監測項目 | CBC、肝功能（ALT/AST/Bilirubin）、血壓、皮膚反應 |
| 處置防護 | 口服藥物，遵循一般藥物處置規範即可 |

## 安全性考量

**主要警語：**
- 肝毒性：可能出現嚴重肝損傷，需定期監測肝功能
- 手足皮膚反應（HFSR）：常見不良反應
- 高血壓：需監測血壓

**禁忌症：**
請參考原廠仿單




### 藥物-食物交互作用 (DFI)

<div class="dfi-source">資料來源：<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>（原文內容請參閱該網站）</div>

**high-fat foods** 🟡 Moderate
- 影響：影響藥物吸收。可能增強藥效。
- 建議：建議避免併用。

**葡萄柚汁** 🟡 Moderate
- 影響：可能增強藥效。
- 建議：建議避免併用。避免食用葡萄柚或葡萄柚汁。

### 藥物-草藥交互作用 (DHI)

**聖約翰草（貫葉連翹）** 🔴 Major
- 影響：聖約翰草降低標靶藥物療效
- 建議：禁止併用


### 藥物-疾病注意事項 (DDSI)

<div class="ddsi-source">資料來源：<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>（原文內容請參閱該網站）</div>

**Lung Diseases** 🟡 Moderate
- 應謹慎使用本藥物。可能有致命風險。出現症狀時應考慮停藥。

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
雖然 SARC024 和 REGOSARC 試驗已探討 regorafenib 用於脂肪肉瘤，但結果顯示在脂肪肉瘤亞組中療效有限。這與其他軟組織肉瘤亞型（如平滑肌肉瘤、滑膜肉瘤）的正面結果形成對比。然而，由於仍有部分患者可能獲益，且缺乏其他有效治療選擇，在充分知情同意下可考慮使用。

**若要推進需要：**
- 根據 SARC024 和 REGOSARC 試驗結果，謹慎評估患者是否適合
- 密切監測肝功能和皮膚反應
- 探索與其他療法（如免疫治療）的組合方案
- 考慮生物標記物以篩選可能獲益的患者亞群

---

## 相關藥物報告

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - 證據等級 L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - 證據等級 L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - 證據等級 L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - 證據等級 L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - 證據等級 L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Regorafenib老藥新用驗證報告. https://twtxgnn.yao.care/drugs/regorafenib/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_regorafenib,
  title = {Regorafenib老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/regorafenib/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
